The info in this paper was already published last fall as a congress poster.Potent antioxidant and mitochondrial-protective effects of ATH434, a moderate affinity iron chaperone
AffiliationsDOI: 10.1016/j.jbc.2025.110595Free article
- PMID: 40812418
Abstract
A plethora of neurologic disease presents with brain iron accumulation. Among these disorders are Parkinson's disease (PD) and Multiple System Atrophy (MSA). Development of interventions logically has focused on the iron-dependent oxidant stress characteristic of these pathologies. This focus is represented by the use of iron chelators on the one hand and antioxidant therapy on the other. Here we provide evidence that ATH434, a small molecule drug candidate with similar and moderate affinity for both ferrous and ferric iron (Kd ∼10-6) exhibits both electron (ET) and hydrogen atom transfer (HAT) antioxidant activity. Previous studies have shown that ATH434 promotes cellular iron efflux, reduces excess brain iron and aggregated α-synuclein, improves neuronal survival, and restores motor performance in murine PD and MSA models. ATH434 has been granted Orphan drug and Fast Track designation by the FDA. Here we have established that ATH434 is a robust antioxidant. We have demonstrated that it protects mitochondrial function and suppresses lipid hydroperoxidation in a menadione-induced model of oxidative stress in a glutamatergic neuronal cell line, HT22. Comparison of the electron and hydrogen atom transfer activities of ATH434 with structurally-related congeners provided insight into this compound's structural features that support its varied antioxidant activity. These behaviors were consistent with the fact that cyclic voltammetry demonstrated ATH434 exhibits a chemically-reversible electrode potential of 328.5 mV, unique to all antioxidants and iron chelators examined in this report. Our results indicate that ATH434 has the capacity to manage excess tissue iron and the oxidant stress induced by that iron.
Keywords: ATH434; antioxidant; brain iron accumulation; iron chaperone; mitochondrial protection;
The Seahorse metabolic analysis was not included in this paper. Perhaps in the next Kosman paper.
Full paper: https://www.jbc.org/article/S0021-9258(25)02446-9/fulltext
- Forums
- ASX - By Stock
- ATH
- A new ATH434 paper by Kosman et al
ATH
alterity therapeutics limited
Add to My Watchlist
0.00%
!
1.3¢

A new ATH434 paper by Kosman et al
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
1.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $119.6M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
6 | 762445 | 1.4¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
1.3¢ | 624947 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
6 | 762445 | 0.014 |
56 | 24215222 | 0.013 |
30 | 18151483 | 0.012 |
13 | 5569965 | 0.011 |
22 | 12217700 | 0.010 |
Price($) | Vol. | No. |
---|---|---|
0.013 | 624947 | 2 |
0.014 | 15822628 | 14 |
0.015 | 19191428 | 12 |
0.016 | 3635011 | 12 |
0.017 | 5708424 | 11 |
Last trade - 09.15am 21/08/2025 (20 minute delay) ? |
Featured News
ATH (ASX) Chart |
Day chart unavailable
The Watchlist
RC1
REDCASTLE RESOURCES LIMITED
Ronald Miller, Non-Executive Director
Ronald Miller
Non-Executive Director
SPONSORED BY The Market Online